Patent ID: 11866786
Assignee: NUCLEIX LTD.
Field: Medical technology (Instruments)
Classification: CPC C  G | IPC C

Claim 6:
7. The method of claim 1, further comprising:
providing first and second control DNA, each comprising human cell line-derived DNA, wherein the first control DNA comprises DNA from a human cell line in which the at least one restriction locus is at least 75% methylated, and the second control DNA comprises DNA from a human cell line in which one or more of the at least one restriction locus is at least 75% unmethylated;
digesting the first and second control DNA with the methylation-sensitive restriction endonuclease to provide a first digested control DNA and a second digested control DNA; and
amplifying the first digested control DNA and second digested control DNA to provide a first control DNA amplification product and a second control DNA amplification product;
generating a separate fluorescent signal from each of the at least one restriction locus amplification product, the control locus amplification product, the first control DNA amplification product, and the second control DNA amplification product, wherein each separate fluorescent signal correlates with the amount of the corresponding amplification product and adequate amplification is defined as a fluorescence level above 100,000 units for each separate fluorescent signal, wherein detection of adequate amplification of the at least one restriction locus and the control locus in the first control DNA is indicative of successful DNA amplification, and wherein low or absence of amplification of one or more of the at least one restriction locus concomitant with normal amplification of the control locus in the second control DNA is indicative of successful DNA digestion.